Skip to main content
SpringerLink
Log in

Is there a need for weed? The role of cannabinoids in managing neuropathic pain

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Baastrup C, Finnerup, NB. Pharmacological management of neuropathic pain following spinal cord injury. CNS Drugs 2008; 22(6): 455–75

    Article  PubMed  CAS  Google Scholar 

  2. Scadding J. Neuropathic pain. ACNR 2003 May–Jun; 3(2): 8, 10, 12, 14

    Google Scholar 

  3. Pain. Merck manual [online]. Available from URL: http://www.merck.com [Accessed 2009 Feb 20]

  4. Martín Fontelles MI, Goicoechea García C. Role of cannabinoids in the management of neuropathic pain. CNS Drugs 2008; 22(8): 645–53

    Article  PubMed  Google Scholar 

  5. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006 Jan; 147Suppl. 1: S163–71

    PubMed  CAS  Google Scholar 

  6. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812–9

    Article  PubMed  Google Scholar 

  7. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabil 2003; 17(1): 21–9

    Article  Google Scholar 

  8. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517–26

    Article  PubMed  CAS  Google Scholar 

  9. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised, double-blind, placebo-controlled, crossover trial. BMJ 2004; 329(7460): 253–7

    Article  PubMed  CAS  Google Scholar 

  10. Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006; 253(10): 1337–41

    Article  PubMed  CAS  Google Scholar 

  11. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68(7): 515–21

    Article  PubMed  CAS  Google Scholar 

  12. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004; 112(3): 299–36

    Article  PubMed  Google Scholar 

  13. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290(13): 1757–62

    Article  PubMed  CAS  Google Scholar 

  14. Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuro-pharmacology 2005; 48(8): 1164–71

    CAS  Google Scholar 

  15. Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain: a randomized controlled trial. Wien Klin Worchenschr 2006; 118(11–12): 327–35

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Is there a need for weed? The role of cannabinoids in managing neuropathic pain. Drugs Ther. Perspect 25, 11–13 (2009). https://doi.org/10.2165/0042310-200925040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925040-00004

Search

Navigation